ArticleRheumatology advances in practice2019
Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen.
Article in Rheumatology advances in practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Glucocorticoid-induced adrenal insufficiency: physiological dose tapering promotes recovery.Endocrine connections · 2026Article
- Effectiveness of a 26-week glucocorticoid taper in giant cell arteritis treated with tocilizumab in real-world clinical practice: a single-centre cohort study.Rheumatology advances in practice · 2025Article
- Adrenal insufficiency in giant cell arteritis.Rheumatology advances in practice · 2025Article
- Giant cell arteritis: reviewing the advancing diagnostics and management.Eye (London, England) · 2023Review
- Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.RMD open · 2023Article
- Frequency of visual involvement in a 10-year interdisciplinary cohort of patients with giant cell arteritis.Clinical medicine (London, England) · 2023Article
- Large-vessel vasculitis.Nature reviews. Disease primers · 2022Review
- Improving the quality of care for people with giant cell arteritis.Clinical medicine (London, England) · 2021Article
- Validating a diagnostic GCA ultrasonography service against temporal artery biopsy and long-term clinical outcomes.Clinical rheumatology · 2020Article
- The relationship between glycated haemoglobin levels and the risk of giant cell arteritis - a case-control study.Rheumatology advances in practice · 2020Article
- Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis.Rheumatology advances in practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have reviewed the literature to form a bespoke regimen for daily oral prednisolone (DP) in GCA. Initial DP in clinical trials is 40-60 mg daily, but relapse rates are 67-92%. Cumulative prednisolone (CP) of 3.2 and 3.9 g (at 6 months) resulted in a relapse rate of 83 and 67%, respectively; and 3 and 3.9 g (at 12 months) resulted in 92 and 82% relapse, respectively. CP was 6.2-7.1 g in the first year. Mean DP was 18.8 mg at 3 months and 6.6-7.4 mg at 12 months. The duration of treatment with prednisolone for GCA was 22-26 months. The CP to achieve discontinuation was 6.5-12.1 g. Using these data, the Norwich regimen starts DP at 1 mg/kg/day of lean body mass, discontinuing over 100 weeks. For the average UK woman, initial DP is 45 mg daily, reaching 21 mg daily by 12 weeks and 6 mg daily by 52 weeks. The CP for the average UK woman would be 6.5 g at 52 weeks and 7.4 g to discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.